Gene Tx For Renal Disease With Purespring CEO Richard Francis
Business Of Biotech
00:00
Are You Just Opening Up Opportunities for a Whole Bunch of Questions?
We've ascertained the potential for large patient populations without, without namin any specific indications. We want to make sure we billion on manufacturing capability to launch or products into the market. And then too a, you don't move into what potential clinical volumes you might be looking at in the not too distant future. I think if we're going to go into big populations, we can't expect healthe systems to digest big, big prices. So how do we avoid that? Knowing that tha, the cost of developing research and developing tetopops is realy high and cost of end-of-life care will also be high. That's why were redressing those now. It's
Transcript
Play full episode
